Activation of human erythrocyte, brain, aorta, muscle, and ocular tissue aldose reductase

Satish Srivastava, Naseem Ansari, Gregory A. Hair, Sanjay Awasthi, Ballabh Das

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Based upon kinetic, structural, and immunologic properties, we have demonstrated that human tissues have three major forms of aldo-keto reductases: aldose reductase (AR), and aldehyde reductases I (AR I) and II (AR II). The proposed subunit compositions are AR, alpha; AR I, alpha-beta; and AR II, delta. Only AR can effectively reduce glucose to sorbitol. The beta subunits in AR I alter the substrate specificity of AR and prevent conformational changes required for the activation of alpha subunits. Partially purified AR (by DE-52) from human erythrocytes expresses biphasic kinetics with glucose and glyceraldehyde. The enzyme can be activated with glucose + glucose-6-P + NADPH and is strongly inhibited by sorbinil, alrestatin, and quercetrin, and by ADP, 2,3DPG, 1,3DPG, and 3PGA. The activated enzyme expresses monophasic kinetics with substrates (Km glucose < 1 mmol/L) and is less susceptible to inhibition by synthetic AR inhibitors and phosphorylated intermediates. The enzyme from human brain, aorta, muscle, and ocular tissues was also activated under similar conditions. Erythrocyte enzyme was activated by incubation of blood with 30 to 50 mmol/L glucose. In diabetic subjects with blood sugar levels higher than 250 mg%, almost all the erythrocyte enzyme exists in the activated form. As demonstrated by enzyme-linked immunosorbent assay (ELISA), the increase in AR activity (in vivo and in vitro) was due to the activation of the enzyme and not to the de novo synthesis. In each case, the activation of the enzyme was confirmed by NADPH oxidation and the formation of proportionate amounts of sorbitol.

Original languageEnglish (US)
Pages (from-to)114-118
Number of pages5
JournalMetabolism
Volume35
Issue number4 SUPPL. 1
DOIs
StatePublished - 1986

Fingerprint

Aldehyde Reductase
Aorta
Erythrocytes
Muscles
Brain
Glucose
Enzymes
Enzyme Activation
Sorbitol
L-glucuronate reductase
NADP
Glyceraldehyde
Substrate Specificity
Adenosine Diphosphate
Blood Glucose
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Activation of human erythrocyte, brain, aorta, muscle, and ocular tissue aldose reductase. / Srivastava, Satish; Ansari, Naseem; Hair, Gregory A.; Awasthi, Sanjay; Das, Ballabh.

In: Metabolism, Vol. 35, No. 4 SUPPL. 1, 1986, p. 114-118.

Research output: Contribution to journalArticle

Srivastava, Satish ; Ansari, Naseem ; Hair, Gregory A. ; Awasthi, Sanjay ; Das, Ballabh. / Activation of human erythrocyte, brain, aorta, muscle, and ocular tissue aldose reductase. In: Metabolism. 1986 ; Vol. 35, No. 4 SUPPL. 1. pp. 114-118.
@article{c14acde7acd0403785f38ff667c33583,
title = "Activation of human erythrocyte, brain, aorta, muscle, and ocular tissue aldose reductase",
abstract = "Based upon kinetic, structural, and immunologic properties, we have demonstrated that human tissues have three major forms of aldo-keto reductases: aldose reductase (AR), and aldehyde reductases I (AR I) and II (AR II). The proposed subunit compositions are AR, alpha; AR I, alpha-beta; and AR II, delta. Only AR can effectively reduce glucose to sorbitol. The beta subunits in AR I alter the substrate specificity of AR and prevent conformational changes required for the activation of alpha subunits. Partially purified AR (by DE-52) from human erythrocytes expresses biphasic kinetics with glucose and glyceraldehyde. The enzyme can be activated with glucose + glucose-6-P + NADPH and is strongly inhibited by sorbinil, alrestatin, and quercetrin, and by ADP, 2,3DPG, 1,3DPG, and 3PGA. The activated enzyme expresses monophasic kinetics with substrates (Km glucose < 1 mmol/L) and is less susceptible to inhibition by synthetic AR inhibitors and phosphorylated intermediates. The enzyme from human brain, aorta, muscle, and ocular tissues was also activated under similar conditions. Erythrocyte enzyme was activated by incubation of blood with 30 to 50 mmol/L glucose. In diabetic subjects with blood sugar levels higher than 250 mg{\%}, almost all the erythrocyte enzyme exists in the activated form. As demonstrated by enzyme-linked immunosorbent assay (ELISA), the increase in AR activity (in vivo and in vitro) was due to the activation of the enzyme and not to the de novo synthesis. In each case, the activation of the enzyme was confirmed by NADPH oxidation and the formation of proportionate amounts of sorbitol.",
author = "Satish Srivastava and Naseem Ansari and Hair, {Gregory A.} and Sanjay Awasthi and Ballabh Das",
year = "1986",
doi = "10.1016/0026-0495(86)90199-X",
language = "English (US)",
volume = "35",
pages = "114--118",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - Activation of human erythrocyte, brain, aorta, muscle, and ocular tissue aldose reductase

AU - Srivastava, Satish

AU - Ansari, Naseem

AU - Hair, Gregory A.

AU - Awasthi, Sanjay

AU - Das, Ballabh

PY - 1986

Y1 - 1986

N2 - Based upon kinetic, structural, and immunologic properties, we have demonstrated that human tissues have three major forms of aldo-keto reductases: aldose reductase (AR), and aldehyde reductases I (AR I) and II (AR II). The proposed subunit compositions are AR, alpha; AR I, alpha-beta; and AR II, delta. Only AR can effectively reduce glucose to sorbitol. The beta subunits in AR I alter the substrate specificity of AR and prevent conformational changes required for the activation of alpha subunits. Partially purified AR (by DE-52) from human erythrocytes expresses biphasic kinetics with glucose and glyceraldehyde. The enzyme can be activated with glucose + glucose-6-P + NADPH and is strongly inhibited by sorbinil, alrestatin, and quercetrin, and by ADP, 2,3DPG, 1,3DPG, and 3PGA. The activated enzyme expresses monophasic kinetics with substrates (Km glucose < 1 mmol/L) and is less susceptible to inhibition by synthetic AR inhibitors and phosphorylated intermediates. The enzyme from human brain, aorta, muscle, and ocular tissues was also activated under similar conditions. Erythrocyte enzyme was activated by incubation of blood with 30 to 50 mmol/L glucose. In diabetic subjects with blood sugar levels higher than 250 mg%, almost all the erythrocyte enzyme exists in the activated form. As demonstrated by enzyme-linked immunosorbent assay (ELISA), the increase in AR activity (in vivo and in vitro) was due to the activation of the enzyme and not to the de novo synthesis. In each case, the activation of the enzyme was confirmed by NADPH oxidation and the formation of proportionate amounts of sorbitol.

AB - Based upon kinetic, structural, and immunologic properties, we have demonstrated that human tissues have three major forms of aldo-keto reductases: aldose reductase (AR), and aldehyde reductases I (AR I) and II (AR II). The proposed subunit compositions are AR, alpha; AR I, alpha-beta; and AR II, delta. Only AR can effectively reduce glucose to sorbitol. The beta subunits in AR I alter the substrate specificity of AR and prevent conformational changes required for the activation of alpha subunits. Partially purified AR (by DE-52) from human erythrocytes expresses biphasic kinetics with glucose and glyceraldehyde. The enzyme can be activated with glucose + glucose-6-P + NADPH and is strongly inhibited by sorbinil, alrestatin, and quercetrin, and by ADP, 2,3DPG, 1,3DPG, and 3PGA. The activated enzyme expresses monophasic kinetics with substrates (Km glucose < 1 mmol/L) and is less susceptible to inhibition by synthetic AR inhibitors and phosphorylated intermediates. The enzyme from human brain, aorta, muscle, and ocular tissues was also activated under similar conditions. Erythrocyte enzyme was activated by incubation of blood with 30 to 50 mmol/L glucose. In diabetic subjects with blood sugar levels higher than 250 mg%, almost all the erythrocyte enzyme exists in the activated form. As demonstrated by enzyme-linked immunosorbent assay (ELISA), the increase in AR activity (in vivo and in vitro) was due to the activation of the enzyme and not to the de novo synthesis. In each case, the activation of the enzyme was confirmed by NADPH oxidation and the formation of proportionate amounts of sorbitol.

UR - http://www.scopus.com/inward/record.url?scp=0022619321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022619321&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(86)90199-X

DO - 10.1016/0026-0495(86)90199-X

M3 - Article

C2 - 3083202

AN - SCOPUS:0022619321

VL - 35

SP - 114

EP - 118

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 4 SUPPL. 1

ER -